



September 7, 2021

**UNITED PARCEL SERVICE  
SIGNATURE REQUIRED**

Abdur-Rahmaan Felder  
Ar-Rahmah Pharm, LLC  
14625 Baltimore Ave., Suite 885  
Laurel, MD 20707

RE: 614578

Dea (aou2 Ts( (aou2 .e )7)2.2 AN)-1356 (bdur)aou2 -LR1.8 (a)20a6 ha

---

---

---

---

---



This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.

Please notify FDA in writing, within 15 working days of receipt of this letter of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.

Your written reply to the above violations should be directed to Rob Genzel Jr. with the FDA via email at [CFSANResponse@fda.hhs.gov](mailto:CFSANResponse@fda.hhs.gov). If you have any questions, you may also email at [CFSANResponse@fda.hhs.gov](mailto:CFSANResponse@fda.hhs.gov).

**FTC Cease and Desist Demand:** In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. *POM Wonderful LLC*, 155 F.T.C. 1, 60-61, (2013), *aff'd in relevant part*, 777 F.3d 478 (D.C. Cir. 2015); *Daniel Chapter One*, FTC Dkt. No. 9239, 2009 WL 5160000 at \*16-19 (F.T.C. Dec. 24, 2009), *aff'd*, 405 Fed. Appx. 505 (D.C. Cir. 2010); *Removatron Int'l Corp.*, 111 F.T.C. 206, 297-99 (1988), *aff'd*, 884 F.2d 1489, 1496 (1st Cir. 1989); see also, *FTC v. Direct Mktg. Concepts*, 569 F. Supp. 2d 285276 Ttn3.5 O/TT2 12 0 Td3 Tc - o (u)-47.1 .3 (200M .31)9 (i)57.9 (al)-9.6 (sl)-9.6 (s(c)-17 (.)-009.5 (1988))-69.5 (

